Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (63)

II-01Thomas Dorlo

Miltefosine treatment failure in visceral leishmaniasis in Nepal is associated with low drug exposure

Wednesday 14:50-16:20

II-02

Using Optimal Design Methods to Help the Design of a Paediatric Pharmacokinetic Study

Wednesday 14:50-16:20

II-03

Influence of the ratio of the sample sizes between the two stages of an adaptive design: application for a population pharmacokinetic study in children

Wednesday 14:50-16:20

II-04Thomas Dumortier

Using a model-based approach to address FDA’s midcycle review concerns by demonstrating the contribution of everolimus to the efficacy of its combination with low exposure tacrolimus in liver transplantation

Wednesday 14:50-16:20

II-05Mike Dunlavey

Support in PML for Absorption Time Lag via Transit Compartments

Wednesday 14:50-16:20

II-06Charles Ernest

Optimal design of a dichotomous Markov-chain mixed-effect sleep model

Wednesday 14:50-16:20

II-07Christine Falcoz

PKPD Modeling of Imeglimin Phase IIa Monotherapy Studies in Type 2 Diabetes Mellitus (T2DM)

Wednesday 14:50-16:20

II-08

Population pharmacokinetics of Zidovudine and its metabolite in HIV-1 infected children: Evaluation doses recommended

Wednesday 14:50-16:20

II-09

drugCARD: a database of anti-cancer treatment regimens and drug combinations

Wednesday 14:50-16:20

II-10Martin Fink

Animal Health Modeling & Simulation Society (AHM&S): A new society promoting model-based approaches for a better integration and understanding of quantitative pharmacology in Veterinary Sciences

Wednesday 14:50-16:20

II-11Sylvain Fouliard

Semi-mechanistic population PKPD modelling of a surrogate biomarker

Wednesday 14:50-16:20

II-12Nicolas Frances

A semi-physiologic mathematical model describing pharmacokinetic profile of an IgG monoclonal antibody mAbX after IV and SC administration in human FcRn transgenic mice.

Wednesday 14:50-16:20

II-13

: Introducing DDMoRe’s framework within an existing enterprise modelling and simulation environment.

Wednesday 14:50-16:20

II-14

A Novel PBPK Approach for mAbs and its Implications in the Interpretation of Classical Compartment Models

Wednesday 14:50-16:20

II-15Aline Fuchs

Population pharmacokinetic study of gentamicin: a retrospective analysis in a large cohort of neonate patients

Wednesday 14:50-16:20

II-16Aurelie Gautier

Pharmacokinetics of Canakinumab and pharmacodynamics of IL-1β binding in cryopyrin associated periodic fever, a step towards personalized medicine

Wednesday 14:50-16:20

II-17

A dynamically integrative PKPD model to predict the efficacy of marbofloxacin treatment regimens for bovine Mannheimia hemolytica infection

Wednesday 14:50-16:20

II-18Peter Gennemark

Incorporating model structure uncertainty in model-based drug discovery

Wednesday 14:50-16:20

II-19Eva Germovsek

Age-Corrected Creatinine is a Significant Covariate for Gentamicin Clearance in Neonates

Wednesday 14:50-16:20

II-20

Comparison of Analysis Methods for Population Exposure-Response in Thorough QT Studies

Wednesday 14:50-16:20

II-21Parviz Ghahramani

Population PKPD Modeling of Milnacipran Effect on Blood Pressure and Heart Rate Over 24-Hour Period Using Ambulatory Blood Pressure Monitoring in Normotensive and Hypertensive Patients With Fibromyalgia

Wednesday 14:50-16:20

II-22Ekaterina Gibiansky

Immunogenicity in PK of Monoclonal Antibodies: Detection and Unbiased Estimation of Model Parameters

Wednesday 14:50-16:20

II-23Leonid Gibiansky

Monoclonal Antibody-Drug Conjugates (ADC): Simplification of Equations and Model-Independent Assessment of Deconjugation Rate

Wednesday 14:50-16:20

II-24Pascal Girard

Tumor size model and survival analysis of cetuximab and various cytotoxics in patients treated for metastatic colorectal cancer

Wednesday 14:50-16:20

II-25Sophie Gisbert

Is it possible to use the plasma and urine pharmacokinetics of a monoclonal antibody (mAb) as an early marker of efficacy in membranous nephropathy (MN)?

Wednesday 14:50-16:20

II-26Timothy Goggin

Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

Wednesday 14:50-16:20

II-27Roberto Gomeni

Implementing adaptive study design in clinical trials for psychiatric disorders using band-pass filtering approach

Wednesday 14:50-16:20

II-28José David Gómez-Mantilla

Tailor-made dissolution profile comparisons using in vitro-in vivo correlation models.

Wednesday 14:50-16:20

II-29Ignacio Gonzalez-Garcia

Simultaneous Modelling Of Fexofenadine In In Vitro Cell Culture And In Situ Experiments

Wednesday 14:50-16:20

II-30Sathej Gopalakrishnan

Towards assessing therapy failure in HIV disease: estimating in vivo fitness characteristics of viral mutants by an integrated statistical-mechanistic approach

Wednesday 14:50-16:20

II-31Verena Gotta

Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients

Wednesday 14:50-16:20

II-32Bruce Green

Clinical Application of a K-PD Warfarin Model for Bayesian Dose Individualisation in Primary Care

Wednesday 14:50-16:20

II-33Zheng Guan

The influence of variability in serum prednisolone pharmacokinetics on clinical outcome in children with nephrotic syndrome, based on salivary sampling combined with translational modeling and simulation approaches from healthy adult volunteers

Wednesday 14:50-16:20

II-34Monia Guidi

Impacts of environmental, clinical and genetic factors on the response to vitamin D supplementation in HIV-positive patients

Wednesday 14:50-16:20

II-35

Tacrolimus in pediatric liver recipients: population pharmacokinetic analysis during the first year post transplantation

Wednesday 14:50-16:20

II-36Chihiro Hasegawa

Modeling & simulation of ONO-4641, a sphingosine 1-phosphate receptor modulator, to support dose selection with phase 1 data

Wednesday 14:50-16:20

II-37Michael Heathman

The Application of Drug-Disease and Clinical Utility Models in the Design of an Adaptive Seamless Phase 2/3 Study

Wednesday 14:50-16:20

II-38Emilie Hénin

Optimization of sorafenib dosing regimen using the concept of utility

Wednesday 14:50-16:20

II-39Eef Hoeben

Prediction of Serotonin 2A Receptor (5-HT2AR) Occupancy in Man From Nonclinical Pharmacology Data. Exposure vs. 5-HT2AR Occupancy Modeling Used to Help Design a Positron Emission Tomography (PET) Study in Healthy Male Subjects.

Wednesday 14:50-16:20

II-40

Usefulness of Weibull-Type Absorption Model for the Population Pharmacokinetic Analysis of Pregabalin

Wednesday 14:50-16:20

II-41Andrew Hooker

Platform for adaptive optimal design of nonlinear mixed effect models.

Wednesday 14:50-16:20

II-42Daniel Hovdal

PKPD modelling of drug induced changes in thyroxine turnover in rat

Wednesday 14:50-16:20

II-43Hwi-yeol Yun

Evaluation of FREM and FFEM including use of model linearization

Wednesday 14:50-16:20

II-44Ibrahim Ince

Oral bioavailability of the CYP3A substrate midazolam across the human age range from preterm neonates to adults

Wednesday 14:50-16:20

II-45Lorenzo Ridolfi

Predictive Modelling Environment – Infrastructure and functionality for pharmacometric activities in R&D

Wednesday 14:50-16:20

II-46Masoud Jamei

Accounting for sex effect on QT prolongation by quinidine: A simulation study using PBPK linked with PD

Wednesday 14:50-16:20

II-47Alvaro Janda

Application of optimal control methods to achieve multiple therapeutic objectives: Optimization of drug delivery in a mechanistic PK/PD system

Wednesday 14:50-16:20

II-48Nerea Jauregizar

Pharmacokinetic/Pharmacodynamic modeling of time-kill curves for echinocandins against Candida.

Wednesday 14:50-16:20

II-49Roger Jelliffe

Multiple Model Optimal Experimental Design for Pharmacokinetic Applications

Wednesday 14:50-16:20

II-50

Population Pharmacokinetics of Piperacillin in Burn Patients

Wednesday 14:50-16:20

II-51Jeremie Guedj

Modeling Early Viral Kinetics with Alisporivir: Interferon-free Treatment and SVR Predictions in HCV G2/3 patients

Wednesday 14:50-16:20

II-52Claire Johnston

A population approach to investigating hepatic intrinsic clearance in old age: Pharmacokinetics of paracetamol and its metabolites

Wednesday 14:50-16:20

II-53Niclas Jonsson

Population PKPD analysis of weekly pain scores after intravenously administered tanezumab, based on pooled Phase 3 data in patients with osteoarthritis of the knee or hip

Wednesday 14:50-16:20

II-54Marija Jovanovic

Effect of Carbamazepine Daily Dose on Topiramate Clearance – Population Modelling Approach

Wednesday 14:50-16:20

II-55Rasmus Juul Kildemoes

Pharmacokinetic modelling as a tool to assess transporter involvement in vigabatrin absorption

Wednesday 14:50-16:20

II-56Matts Kågedal

A modelling approach allowing different nonspecific uptake in the reference region and regions of interest – Opening up the possibility to use white matter as a reference region in PET occupancy studies.

Wednesday 14:50-16:20

II-57Ana Novakovic

Application of Item Response Theory to EDSS Modeling in Multiple Sclerosis

Wednesday 14:50-16:20

II-58Takayuki Katsube

Pharmacokinetic/pharmacodynamic modeling and simulation for concentration-dependent bactericidal activity of a bicyclolide, modithromycin

Wednesday 14:50-16:20

II-59Irene-Ariadne Kechagia

Population pharmacokinetic analysis of colistin after administration of inhaled colistin methanesulfonate.

Wednesday 14:50-16:20

II-60Ron Keizer

cPirana: command-line user interface for NONMEM and PsN

Wednesday 14:50-16:20

II-61Frank Kloprogge

Population pharmacokinetics and pharmacodynamics of lumefantrine in pregnant women with uncomplicated P. falciparum malaria.

Wednesday 14:50-16:20

II-62Gilbert Koch

Solution and implementation of distributed lifespan models

Wednesday 14:50-16:20

II-64Julia Korell

Gaining insight into red blood cell destruction mechanisms using a previously developed semi-mechanistic model

Wednesday 14:50-16:20